AGuIX® preferentially accumulates in tumor
through natural blood flow
The ultrasmall size of AGuIX® (∼ 5 nanometers) combined with the specific physiology of tumors (leaky tumor vasculature) allow its deep and prolonged uptake after intravenous administration resulting in an accumulation of AGuIX® into the tumors. This well-known phenomenon is called Enhanced Permeation and Retention (EPR) effect and applies to many cancer types. In contrary, healthy tissues do not have a leaky vasculature, preventing AGuIX® from any diffusion to these tissues. This selective targeting supports a large therapeutic window (>24 hours).
Enhanced Permeability and Retention (EPR) effect